KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Revenue (2016 - 2025)

Historic Revenue for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $3.2 billion.

  • Vertex Pharmaceuticals' Revenue rose 954.67% to $3.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $12.0 billion, marking a year-over-year increase of 890.37%. This contributed to the annual value of $12.0 billion for FY2025, which is 890.37% up from last year.
  • According to the latest figures from Q4 2025, Vertex Pharmaceuticals' Revenue is $3.2 billion, which was up 954.67% from $3.1 billion recorded in Q3 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Revenue ranged from a high of $3.2 billion in Q4 2025 and a low of $1.7 billion during Q1 2021
  • Over the past 5 years, Vertex Pharmaceuticals' median Revenue value was $2.5 billion (recorded in 2023), while the average stood at $2.5 billion.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Revenue skyrocketed by 2898.25% in 2021 and then skyrocketed by 295.84% in 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Revenue (Quarter) stood at $2.1 billion in 2021, then rose by 11.1% to $2.3 billion in 2022, then grew by 9.34% to $2.5 billion in 2023, then increased by 15.66% to $2.9 billion in 2024, then increased by 9.55% to $3.2 billion in 2025.
  • Its last three reported values are $3.2 billion in Q4 2025, $3.1 billion for Q3 2025, and $3.0 billion during Q2 2025.